Anavex Life Sciences Corp. (NASDAQ: AVXL) shares shed 1.4% to $4.17 as the company revealed Tuesday that the Food and Drug Administration's Office of Orphan Product Development has granted Orphan Drug Designation to its ANAVEX 2-73 for infantile spasms treatment. Share volume was 238,000, compared to an all-day average of 752,000
